GrippeEspagneV1, Main, Exploration, bibRecord, 000546

Dynamic modelling of infectious diseases: an application to the economic evaluation of influenza vaccination.

Identifieur interne : 000546 ( Main/Exploration ); précédent : 000545; suivant : 000547

Dynamic modelling of infectious diseases: an application to the economic evaluation of influenza vaccination.

Auteurs : Roberto Pradas-Velasco [Espagne] ; Fernando Anto Anzas-Villar ; María Puy Martínez-Zárate

Source :

PharmacoEconomics [ 1170-7690 ] ; 2008.

RBID : pubmed:18088158

Descripteurs français

KwdFr :
- Analyse coût-bénéfice (MeSH), Espagne (épidémiologie), Grippe humaine (prévention et contrôle), Grippe humaine (économie), Grippe humaine (épidémiologie), Humains (MeSH), Immunité de groupe (immunologie), Modèles immunologiques (MeSH), Modèles statistiques (MeSH), Vaccination de masse (économie), Vaccins antigrippaux (économie), Économies (MeSH).
MESH :
- immunologie : Immunité de groupe.
- prévention et contrôle : Grippe humaine.
- économie : Grippe humaine, Vaccination de masse, Vaccins antigrippaux.
- épidémiologie : Espagne, Grippe humaine.
- Analyse coût-bénéfice, Humains, Modèles immunologiques, Modèles statistiques, Économies.
Wicri :
- geographic : Espagne.

English descriptors

KwdEn :
- Cost Savings (MeSH), Cost-Benefit Analysis (MeSH), Humans (MeSH), Immunity, Herd (immunology), Influenza Vaccines (economics), Influenza, Human (economics), Influenza, Human (epidemiology), Influenza, Human (prevention & control), Mass Vaccination (economics), Models, Immunological (MeSH), Models, Statistical (MeSH), Spain (epidemiology).
MESH :
- chemical , economics : Influenza Vaccines.
- geographic , epidemiology : Spain.
- economics : Influenza, Human, Mass Vaccination.
- epidemiology : Influenza, Human.
- immunology : Immunity, Herd.
- prevention & control : Influenza, Human.
- Cost Savings, Cost-Benefit Analysis, Humans, Models, Immunological, Models, Statistical.

Abstract

OBJECTIVE

To evaluate the economic efficiency of influenza vaccination using both dynamic and static modelling approaches.

SETTING

The Spanish National Health System.

DESIGN AND METHODS

We modelled the progress of an influenza epidemic in Spain according to the epidemiological pattern of susceptible-->infective-->resistant, employing a non-linear system of ordinary differential equations that enables the measurement of epidemiological effects of an anti-influenza vaccination. We used a decision tree to represent the repercussion on healthcare resources use and on financial resources. The same analyses were conducted using a static approach, and the results were compared. Healthcare costs were valued in euro, year 2005 values.

RESULTS

For the base case, the impact of the healthcare intervention (vaccination) was not efficient from the perspective of the healthcare payer when using a static approach (return rate 0.28 per euro invested in vaccination). Nevertheless, it was efficient when employing a dynamic approach (return rate 1.22 per euro). Furthermore, a considerable freeing of healthcare resources would have been produced over the entire influenza season.

CONCLUSIONS

The indirect effect of vaccination on the non-vaccinated individuals (the 'herd immunity effect') can be greater than the direct effect on individuals vaccinated. This implies that the herd immunity effect needs to be taken into consideration in the economic evaluations of prophylactic measures employed against infectious diseases.

DOI: 10.2165/00019053-200826010-00005
PubMed: 18088158

Affiliations:

Espagne

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 00546
to stream Main, to step Curation: 000546

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Dynamic modelling of infectious diseases: an application to the economic evaluation of influenza vaccination.</title>
<author><name sortKey="Pradas Velasco, Roberto" sort="Pradas Velasco, Roberto" uniqKey="Pradas Velasco R" first="Roberto" last="Pradas-Velasco">Roberto Pradas-Velasco</name>
<affiliation wicri:level="1"><nlm:affiliation>Centro Sagrado Corazón, Logroño, SpainUniversidad de la Rioja, Logroño, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Centro Sagrado Corazón, Logroño, SpainUniversidad de la Rioja, Logroño</wicri:regionArea>
<wicri:noRegion>Logroño</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Anto Anzas Villar, Fernando" sort="Anto Anzas Villar, Fernando" uniqKey="Anto Anzas Villar F" first="Fernando" last="Anto Anzas-Villar">Fernando Anto Anzas-Villar</name>
</author>
<author><name sortKey="Martinez Zarate, Maria Puy" sort="Martinez Zarate, Maria Puy" uniqKey="Martinez Zarate M" first="María Puy" last="Martínez-Zárate">María Puy Martínez-Zárate</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2008">2008</date>
<idno type="RBID">pubmed:18088158</idno>
<idno type="pmid">18088158</idno>
<idno type="doi">10.2165/00019053-200826010-00005</idno>
<idno type="wicri:Area/Main/Corpus">00546</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">00546</idno>
<idno type="wicri:Area/Main/Curation">000546</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000546</idno>
<idno type="wicri:Area/Main/Exploration">000546</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Dynamic modelling of infectious diseases: an application to the economic evaluation of influenza vaccination.</title>
<author><name sortKey="Pradas Velasco, Roberto" sort="Pradas Velasco, Roberto" uniqKey="Pradas Velasco R" first="Roberto" last="Pradas-Velasco">Roberto Pradas-Velasco</name>
<affiliation wicri:level="1"><nlm:affiliation>Centro Sagrado Corazón, Logroño, SpainUniversidad de la Rioja, Logroño, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Centro Sagrado Corazón, Logroño, SpainUniversidad de la Rioja, Logroño</wicri:regionArea>
<wicri:noRegion>Logroño</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Anto Anzas Villar, Fernando" sort="Anto Anzas Villar, Fernando" uniqKey="Anto Anzas Villar F" first="Fernando" last="Anto Anzas-Villar">Fernando Anto Anzas-Villar</name>
</author>
<author><name sortKey="Martinez Zarate, Maria Puy" sort="Martinez Zarate, Maria Puy" uniqKey="Martinez Zarate M" first="María Puy" last="Martínez-Zárate">María Puy Martínez-Zárate</name>
</author>
</analytic>
<series><title level="j">PharmacoEconomics</title>
<idno type="ISSN">1170-7690</idno>
<imprint><date when="2008" type="published">2008</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Cost Savings (MeSH)</term>
<term>Cost-Benefit Analysis (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Immunity, Herd (immunology)</term>
<term>Influenza Vaccines (economics)</term>
<term>Influenza, Human (economics)</term>
<term>Influenza, Human (epidemiology)</term>
<term>Influenza, Human (prevention & control)</term>
<term>Mass Vaccination (economics)</term>
<term>Models, Immunological (MeSH)</term>
<term>Models, Statistical (MeSH)</term>
<term>Spain (epidemiology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Analyse coût-bénéfice (MeSH)</term>
<term>Espagne (épidémiologie)</term>
<term>Grippe humaine (prévention et contrôle)</term>
<term>Grippe humaine (économie)</term>
<term>Grippe humaine (épidémiologie)</term>
<term>Humains (MeSH)</term>
<term>Immunité de groupe (immunologie)</term>
<term>Modèles immunologiques (MeSH)</term>
<term>Modèles statistiques (MeSH)</term>
<term>Vaccination de masse (économie)</term>
<term>Vaccins antigrippaux (économie)</term>
<term>Économies (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="economics" xml:lang="en"><term>Influenza Vaccines</term>
</keywords>
<keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Spain</term>
</keywords>
<keywords scheme="MESH" qualifier="economics" xml:lang="en"><term>Influenza, Human</term>
<term>Mass Vaccination</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Immunité de groupe</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Immunity, Herd</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Grippe humaine</term>
</keywords>
<keywords scheme="MESH" qualifier="économie" xml:lang="fr"><term>Grippe humaine</term>
<term>Vaccination de masse</term>
<term>Vaccins antigrippaux</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Espagne</term>
<term>Grippe humaine</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Cost Savings</term>
<term>Cost-Benefit Analysis</term>
<term>Humans</term>
<term>Models, Immunological</term>
<term>Models, Statistical</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Analyse coût-bénéfice</term>
<term>Humains</term>
<term>Modèles immunologiques</term>
<term>Modèles statistiques</term>
<term>Économies</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Espagne</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p><b>OBJECTIVE</b>
</p>
<p>To evaluate the economic efficiency of influenza vaccination using both dynamic and static modelling approaches.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>SETTING</b>
</p>
<p>The Spanish National Health System.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>DESIGN AND METHODS</b>
</p>
<p>We modelled the progress of an influenza epidemic in Spain according to the epidemiological pattern of susceptible-->infective-->resistant, employing a non-linear system of ordinary differential equations that enables the measurement of epidemiological effects of an anti-influenza vaccination. We used a decision tree to represent the repercussion on healthcare resources use and on financial resources. The same analyses were conducted using a static approach, and the results were compared. Healthcare costs were valued in euro, year 2005 values.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>RESULTS</b>
</p>
<p>For the base case, the impact of the healthcare intervention (vaccination) was not efficient from the perspective of the healthcare payer when using a static approach (return rate 0.28 per euro invested in vaccination). Nevertheless, it was efficient when employing a dynamic approach (return rate 1.22 per euro). Furthermore, a considerable freeing of healthcare resources would have been produced over the entire influenza season.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b>
</p>
<p>The indirect effect of vaccination on the non-vaccinated individuals (the 'herd immunity effect') can be greater than the direct effect on individuals vaccinated. This implies that the herd immunity effect needs to be taken into consideration in the economic evaluations of prophylactic measures employed against infectious diseases.</p>
</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18088158</PMID>
<DateCompleted><Year>2008</Year>
<Month>04</Month>
<Day>11</Day>
</DateCompleted>
<DateRevised><Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">1170-7690</ISSN>
<JournalIssue CitedMedium="Print"><Volume>26</Volume>
<Issue>1</Issue>
<PubDate><Year>2008</Year>
</PubDate>
</JournalIssue>
<Title>PharmacoEconomics</Title>
<ISOAbbreviation>Pharmacoeconomics</ISOAbbreviation>
</Journal>
<ArticleTitle>Dynamic modelling of infectious diseases: an application to the economic evaluation of influenza vaccination.</ArticleTitle>
<Pagination><MedlinePgn>45-56</MedlinePgn>
</Pagination>
<Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate the economic efficiency of influenza vaccination using both dynamic and static modelling approaches.</AbstractText>
<AbstractText Label="SETTING" NlmCategory="METHODS">The Spanish National Health System.</AbstractText>
<AbstractText Label="DESIGN AND METHODS" NlmCategory="METHODS">We modelled the progress of an influenza epidemic in Spain according to the epidemiological pattern of susceptible-->infective-->resistant, employing a non-linear system of ordinary differential equations that enables the measurement of epidemiological effects of an anti-influenza vaccination. We used a decision tree to represent the repercussion on healthcare resources use and on financial resources. The same analyses were conducted using a static approach, and the results were compared. Healthcare costs were valued in euro, year 2005 values.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">For the base case, the impact of the healthcare intervention (vaccination) was not efficient from the perspective of the healthcare payer when using a static approach (return rate 0.28 per euro invested in vaccination). Nevertheless, it was efficient when employing a dynamic approach (return rate 1.22 per euro). Furthermore, a considerable freeing of healthcare resources would have been produced over the entire influenza season.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The indirect effect of vaccination on the non-vaccinated individuals (the 'herd immunity effect') can be greater than the direct effect on individuals vaccinated. This implies that the herd immunity effect needs to be taken into consideration in the economic evaluations of prophylactic measures employed against infectious diseases.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pradas-Velasco</LastName>
<ForeName>Roberto</ForeName>
<Initials>R</Initials>
<AffiliationInfo><Affiliation>Centro Sagrado Corazón, Logroño, SpainUniversidad de la Rioja, Logroño, Spain.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Antoñanzas-Villar</LastName>
<ForeName>Fernando</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="Y"><LastName>Martínez-Zárate</LastName>
<ForeName>María Puy</ForeName>
<Initials>MP</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>New Zealand</Country>
<MedlineTA>Pharmacoeconomics</MedlineTA>
<NlmUniqueID>9212404</NlmUniqueID>
<ISSNLinking>1170-7690</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>T</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D017046" MajorTopicYN="N">Cost Savings</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003362" MajorTopicYN="N">Cost-Benefit Analysis</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D032521" MajorTopicYN="N">Immunity, Herd</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName>
<QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName>
<QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D032541" MajorTopicYN="N">Mass Vaccination</DescriptorName>
<QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018448" MajorTopicYN="N">Models, Immunological</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015233" MajorTopicYN="N">Models, Statistical</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013030" MajorTopicYN="N" Type="Geographic">Spain</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year>
<Month>12</Month>
<Day>20</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2008</Year>
<Month>4</Month>
<Day>12</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2007</Year>
<Month>12</Month>
<Day>20</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">18088158</ArticleId>
<ArticleId IdType="pii">2615</ArticleId>
<ArticleId IdType="doi">10.2165/00019053-200826010-00005</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Pharmacoeconomics. 2002;20(7):475-84</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12093303</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2006 Nov 17;24(47-48):6812-22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17034909</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virus Res. 2004 Jul;103(1-2):101-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15163497</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pharmacoeconomics. 2006;24(4):373-86</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16605283</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Aten Primaria. 2004 Feb 28;33(3):161</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14987501</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Rev Esp Salud Publica. 2006 May-Jun;80(3):219-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16838467</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Gac Sanit. 2006 Jan-Feb;20(1):67-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16539998</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arch Intern Med. 2001 Mar 12;161(5):749-59</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11231710</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Med Decis Making. 2006 Jan-Feb;26(1):38-47</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16495199</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2001 Dec 1;33(11):1879-85</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11692300</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Math Biosci. 2002 Nov-Dec;180:207-35</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12387924</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Stat Med. 1999 Dec 15;18(23):3263-82</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10602150</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Med Clin (Barc). 2004 Oct 23;123(14):532-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15535925</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Gac Sanit. 2003 Nov-Dec;17(6):447-52</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14670250</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 1979 Aug 2;280(5721):361-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">460412</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pediatrics. 2007 Jan;119(1):e22-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17200247</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Med Decis Making. 2003 Jan-Feb;23(1):76-82</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12583457</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Gac Sanit. 2006 Jan-Feb;20(1):4-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16539986</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 1982 Feb 26;215(4536):1053-60</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7063839</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Health Technol Assess. 2003;7(24):iii-x, 1-65</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14499051</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pharmacoeconomics. 2005;23(11):1083-106</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16277546</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Theor Popul Biol. 2004 Mar;65(2):179-91</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14766191</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2007 Jul 20;25(29):5390-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17583392</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Espagne</li>
</country>
</list>
<tree><noCountry><name sortKey="Anto Anzas Villar, Fernando" sort="Anto Anzas Villar, Fernando" uniqKey="Anto Anzas Villar F" first="Fernando" last="Anto Anzas-Villar">Fernando Anto Anzas-Villar</name>
<name sortKey="Martinez Zarate, Maria Puy" sort="Martinez Zarate, Maria Puy" uniqKey="Martinez Zarate M" first="María Puy" last="Martínez-Zárate">María Puy Martínez-Zárate</name>
</noCountry>
<country name="Espagne"><noRegion><name sortKey="Pradas Velasco, Roberto" sort="Pradas Velasco, Roberto" uniqKey="Pradas Velasco R" first="Roberto" last="Pradas-Velasco">Roberto Pradas-Velasco</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippeEspagneV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000546 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000546 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    GrippeEspagneV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:18088158
   |texte=   Dynamic modelling of infectious diseases: an application to the economic evaluation of influenza vaccination.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:18088158" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a GrippeEspagneV1

This area was generated with Dilib version V0.6.37.
Data generation: Fri Sep 25 11:01:38 2020. Site generation: Sat Feb 13 17:38:04 2021

	Serveur d'exploration sur la grippe en Espagne
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur la grippe en Espagne

Dynamic modelling of infectious diseases: an application to the economic evaluation of influenza vaccination.

Dynamic modelling of infectious diseases: an application to the economic evaluation of influenza vaccination.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki